Trial
NCT03709082
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Kansas Medical Center
Collaborators
Pfizer
Condition
HER2-positive Breast Cancer
Intervention
Palbociclib 75mg
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-05